Industry & Trends
Our articles on peptide regulation, the industry and where it is heading, newest first.
Peptide Dosage Chart: Why Most Advice Gets It Wrong
How to vet a peptide supplier: what a real COA and mass spec report look like, common counterfeits, and the verification checklist dosing guides skip.
FDA Peptide Vote 2026: 6 of 7 Backed for the 503A Bulks List
On 23-24 July 2026 the FDA peptide advisory committee backed 6 of 7 peptides for the 503A bulks list. Full vote matrix, and why nothing is legal today.
Running Peptide Protocols: What I've Learned
Lessons from running peptide protocols: most dosing is a guess, tolerance is pathway specific, your source drives antibody risk, and the safety data is thin.
The Case for Peptide Regulation: An Unpopular Opinion
The case for peptide regulation in plain terms: 34 FDA-approved peptides since 2016, about 30% of gray-market vials failing checks, and what it means for you.
BPC-157 Prescription in 2026: Why You Still Can't Get One
How to get a BPC-157 prescription in 2026: you can't. No pharmacy may lawfully compound BPC-157 or TB-500, and July's FDA advisory vote changed nothing.
How AI Is Changing Peptide Research, and What It Means
AI changing peptide research is not hype: discovery has gone from years to weeks. Here is what the peer-reviewed evidence shows, and where it still falls short.
The Peptide Purity Crisis Nobody Talks About
The peptide purity crisis is real: most COAs report HPLC purity only. Here is what endotoxin, TFA and synthesis byproduct testing reveal, and what to check.
Grey Market Peptides: Purity, Endotoxins and the Law
Grey market peptides explained: why no lawful compounding route exists today, plus the purity gaps, endotoxin risks and the testing nobody actually runs.
FDA Compounding Regulations Peptides Users Must Know
FDA compounding regulations peptides users face in 2026: what the PCAC vote and Category 2 removal change for 503A pharmacy access, and what they do not.